Our results showed that SAR131675 treatment significantly reduced dyslipidemia and intrarenal lipid accumulation to the levels comparable to that of non-diabetic db/m mice and subsequently decreased TGF-β and TNF-α levels and oxidative stress. This evidence concerns the gene TGFB1 and metabolic syndrome.